Beauty Bytes with Dr. Kay: Secrets of a Plastic Surgeon™ 671: The Latest Developments on Semaglutides with Dr. Danielle Belardo
Oct 18, 2024
Join cardiologist Dr. Danielle Belardo, a close friend of Dr. Kay, as she reveals groundbreaking developments in the weight loss industry, particularly focusing on semaglutide and its related medications. Discover how these treatments evolve to improve patient outcomes and discuss the end of shortages, enhancing access and affordability for patients. Delve into the importance of personalized treatment plans, the significance of GLP-1 medications, and the emerging role of terzeptide in reshaping weight management strategies.
AI Snips
Chapters
Transcript
Episode notes
Semaglutide Availability Restored
- Semaglutide and similar medications are now widely available without shortages at pharmacies.
- FDA-approved versions are accessible with insurance copays often ranging from zero to $100.
Manjaro Outperforms Ozempic
- Manjaro (and ZepBound) can lead to about 25% weight loss over two years, outperforming Ozempic (Wegovi) which leads to ~16% in 72 weeks.
- Manjaro is a GLP-1 and GIP dual agonist that allows weight loss often at lower doses with fewer side effects.
Individualized Weight Maintenance Dosing
- Patients often maintain weight on much lower doses of Manjaro after reaching goals, sometimes even once monthly.
- Weight maintenance dosing varies widely and should be tailored to the individual, not just highest or zero dose.